The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1510
Celecoxib Safety Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The results of a clinical trial (PRECISION)1 comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib (Celebrex, and generics) with that of ibuprofen and naproxen, which are nonselective, have been described in the lay press in terms that may overestimate the safety of celecoxib.

NSAID PHARMACOLOGY — NSAIDs inhibit the enzyme cyclooxygenase (COX), which is required for synthesis of prostaglandins and thromboxane. COX-1 inhibition blocks the protective effect of prostaglandins on the gastric mucosa, which can cause gastrointestinal toxicity, and has an antiplatelet effect that can cause bleeding. COX-2 inhibition produces therapeutic anti-inflammatory and analgesic effects, but it has effects on vascular endothelium that can be prothrombotic.

Ibuprofen and naproxen inhibit COX-1 more than COX-2. The COX-2 selective NSAID rofecoxib (Vioxx), ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Celecoxib Safety Revisited
Article code: 1510a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian